Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 18/20 | 0.63 |
| ▸ | HTR2C | P28335 | 17/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.49 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14625270 | 0.91 | HTR2A (0.76) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL6034181 | 0.86 | HTR2A (0.63) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL6034633 | 0.82 | HTR2A (0.60) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL27895777 | 0.81 | ALDH1A1 (0.57) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL7025996 | 0.80 | L3MBTL1 (0.86) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL14624892 | 0.80 | HTR2A (0.56) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL14045250 | 0.79 | HTR2A (0.58) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL14624766 | 0.79 | ALDH1A1 (0.51) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL14625157 | 0.79 | ALDH1A1 (0.49) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL14045243 | 0.79 | HTR2A (0.54) | HTR2AHTR2CL3MBTL1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1322602-A1 | SUBSTITUTED CINNAMIC ACID GUANIDIDES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICAMENT, AND TO A MEDICAMENT CONTAINING THESE COMPOUNDS | Aventis Pharma Deutschland GmbH (DE) | 2003-07-02 | — | — | EP | disclosed |
| US-6399824-B1 | FOR THERAPY AND PROPHYLAXIS OF ARRHYTHMIAS, CARDIAC INFRACTION, ISCHEMIC CONDITIONS, ANGINA PECTORIS, SHOCK, FOR PRESERVING AND STORING A TRANSPLANT FOR SURGICAL MEASURE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-06-04 | — | — | US | disclosed |
| US-20020058710-A1 | SUBSTITUTED CINNAMIC, ACID GUANIDIDES, PROCESS FOR THEIR PREPARATION, THEIR USE AS A MEDICAMENT, AND MEDICAMENT COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH. | 2002-05-16 | — | — | US | disclosed |
| WO-2002024637-A1 | SUBSTITUTED CINNAMIC ACID GUANIDIDES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICAMENT, AND TO A MEDICAMENT CONTAINING THESE COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058710-A1 | SUBSTITUTED CINNAMIC, ACID GUANIDIDES, PROCESS FOR THEIR PREPARATION, THEIR USE AS A MEDICAMENT, AND MEDICAMENT COMPRISING THEM | GANC, GMPS, GCDH | HTR2A 2928/4885HTR2C 2232/4885L3MBTL1 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.